MedMira (STU:47M) FCF Margin % : -361.76% (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MedMira FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MedMira's Free Cash Flow for the three months ended in Jan. 2024 was €-0.37 Mil. MedMira's Revenue for the three months ended in Jan. 2024 was €0.10 Mil. Therefore, MedMira's FCF Margin % for the quarter that ended in Jan. 2024 was -361.76%.

As of today, MedMira's current FCF Yield % is -3.36%.

The historical rank and industry rank for MedMira's FCF Margin % or its related term are showing as below:

STU:47M' s FCF Margin % Range Over the Past 10 Years
Min: -491.04 Med: -180.55 Max: -25.28
Current: -491.04

During the past 13 years, the highest FCF Margin % of MedMira was -25.28%. The lowest was -491.04%. And the median was -180.55%.

STU:47M's FCF Margin % is ranked worse than
66.7% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs STU:47M: -491.04

MedMira FCF Margin % Historical Data

The historical data trend for MedMira's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira FCF Margin % Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

FCF Margin %

Get a 7-Day Free Trial

-178.27

-34.46

-25.28

-205.39

-293.58

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-84.75	-450.00	-845.83	-585.19	-361.76

Competitive Comparison of MedMira's FCF Margin %

For the Biotechnology subindustry, MedMira's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MedMira's FCF Margin % falls into.

MedMira FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MedMira's FCF Margin for the fiscal year that ended in Jul. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-0.869	/	0.296
	=	-293.58 %

MedMira's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-0.369	/	0.102
	=	-361.76 %

MedMira FCF Margin % Related Terms

Thank you for viewing the detailed overview of MedMira's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (STU:47M) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (STU:47M) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MMIRF:USA 47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (STU:47M) Headlines

No Headlines